CurrentCareSource GeorgiaPolicy N/A

Skin Substitutes — Medical Policy (coverage criteria)

Customize your policy alerts

Sign up for all CareSource Georgia policy alerts

Know when CareSource Georgia releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Clinical policy governing medical necessity, documentation, and coverage limits for use of skin substitute products (including cellular and tissue-based products) for treatment of chronic wounds, burns, and scar contractures for CareSource Marketplace members.

Policy Summary

PayerCareSource Georgia

PolicySkin Substitutes — Medical Policy (coverage criteria)

Policy CodePolicy N/A

Change TypeMaterial clinical updates (added circulation criteria, documentation expansion, life-expectancy exclusion)

Effective DateDec 1, 2025

Last ReviewAug 27, 2025

Next Review DateN/A

Key ActionObtain prior authorization with documentation of ≥4 weeks standard of care failure and required vascular and wound assessments before ordering skin substitutes.

SourceLink

POLICY UPDATE CHANGES

Added specific circulation criteria for diabetic foot ulcers including ABI, TcPO2, palpable pedal pulses, and Doppler waveforms.

Added a life expectancy consideration that would preclude coverage if it would not allow long-term healing or clinical benefit.

Expanded documentation and treatment plan requirements including debridement, offloading, compression, infection control, and smoking cessation counseling.

3major wound categories

>=50%>=50% area reduction threshold

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentCareSource GeorgiaPolicy N/A

Skin Substitutes — Medical Policy (coverage criteria)

Customize your policy alerts

Sign up for all CareSource Georgia policy alerts

Know when CareSource Georgia releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerCareSource Georgia

PolicySkin Substitutes — Medical Policy (coverage criteria)

Policy CodePolicy N/A

Change TypeMaterial clinical updates (added circulation criteria, documentation expansion, life-expectancy exclusion)

Effective DateDec 1, 2025

Last ReviewAug 27, 2025

Next Review DateN/A

Key ActionObtain prior authorization with documentation of ≥4 weeks standard of care failure and required vascular and wound assessments before ordering skin substitutes.

SourceLink

POLICY UPDATE CHANGES

Added specific circulation criteria for diabetic foot ulcers including ABI, TcPO2, palpable pedal pulses, and Doppler waveforms.

Added a life expectancy consideration that would preclude coverage if it would not allow long-term healing or clinical benefit.

Expanded documentation and treatment plan requirements including debridement, offloading, compression, infection control, and smoking cessation counseling.

3major wound categories

>=50%>=50% area reduction threshold

minimum SOC duration

3max applications without response

Multiplerequired vascular options

Medical Necessity and Covered Indications

Initial therapy: Diabetic foot ulcer

Covered when ALL of the following are met for chronic, non-infected DFU:

DFU initial coverage: 1) Chronic, non-infected diabetic foot ulcer that failed to achieve at least 50% ulcer area reduction after documented standard of care (SOC) treatment for a minimum of 4 weeks with documented compliance; 2) Adequate circulation to the affected extremity demonstrated by ONE of: palpable pedal pulses OR ankle-brachial index (ABI) between 0.7 and 1.2 OR dorsum transcutaneous oxygen (TcPO2) ≥ 30 mm Hg within the last 60 days OR triphasic or biphasic Doppler arterial waveforms at the ankle of the affected leg; 3) Appropriate glycemic control; 4) No wound infection; 5) No response to conventional therapy, including ALL of the following: offloading (pressure relief), appropriate dressings to facilitate healing, and debridement as needed.

Initial therapy: Venous insufficiency ulcer

Covered when ALL of the following are met for chronic, non-infected venous insufficiency ulcers:

Venous ulcer initial coverage: 1) Noninvasive duplex ultrasound documenting chronic venous disease; 2) Adequate perfusion of the involved limb; 3) Appropriate surgical venous interventions (if applicable); 4) Concurrent conventional wound care; 5) Concurrent glycemic management if the patient is diabetic; 6) Duration greater than 6 weeks; 7) Partial-thickness or full-thickness ulcer due to venous insufficiency; 8) No allergy to bovine products; 9) No response to conventional therapy, including ALL of the following: compression therapy, surgical intervention for UVD (if applicable), dressings to maintain a moist wound environment (eg, saline‑moistened dressings, negative pressure wound therapy), and sharp debridement; 10) No wound infection.

Burns

Covered when ONE of the following burn-related criteria are met:

Burn wounds: 1) Temporary wound covering for excised full-thickness and deep partial-thickness burn wounds in individuals who require such a covering prior to autograft placement; OR 2) Treatment of mid-dermal to indeterminate depth burn wounds that typically require debridement and may be expected to heal without autografting.

Other covered indications

Covered when ALL criteria are met:

Scar contracture repair: Repair of scar contractures when more conservative therapeutic options have failed and when used in conjunction with a breast reconstruction procedure.

Pressure redistribution support surfaces for pressure ulcers.

The following general exclusions apply: new quarterly skin substitutes or Q-codes that have not been used outside clinical trials are considered non-covered or investigational. In addition, all liquid or gel skin substitute products or CTPs for ulcer care are non-covered. Skin substitute products that are not on the applicable fee schedule may be considered experimental and not reimbursable.

Skin substitutes are not covered when applied to wounds with active local tissue compromise or when underlying conditions are inadequately controlled. Specifically, placement on an infected, ischemic, or necrotic wound bed is excluded. Coverage is also precluded for patients with inadequate control of underlying conditions or exacerbating factors (for example, active infection, progressive necrosis, active Charcot arthropathy of the ulcer extremity, active vasculitis, or ischemia) until those conditions are managed.

Limitations on frequency and repetition of applications: Greater than 3 applications of a skin substitute/CTP over 12 weeks is non-covered if wound volume has not decreased by at least 50%. Repeat applications after an unsuccessful prior application are not permitted; unsuccessful treatment is defined as an increase in size or depth of the ulcer, no measurable change from baseline, or no sign of significant improvement (eg, granulation, epithelialization, or progress toward closure).

Coverage should not be provided when the member's life expectancy would not allow long-term healing or clinical benefit or when meaningful reduction of substantive morbidity is not expected. This life-expectancy consideration is a condition that precludes coverage for skin substitute application.

Billing, Codes, and Response Metrics

Non-covered / Experimental coding groupmixedNot Covered

Q-codes

Quarterly skin substitutes or Q-codes that have not been used outside clinical trials are non-covered/experimental per policy

Ulcer volume/area response — thresholds and windows

DFU response threshold≥50% reduction in ulcer area/volume after a minimum of 4 weeks of documented standard of care (SOC) with documented compliance

DFU assessment window for initial coverageAssess after at least 4 weeks of SOC; skin substitute considered when ≥50% area reduction not achieved

Continuation/maximum application ruleGreater than 3 applications of a skin substitute over 12 weeks is non-covered if wound volume has not decreased by at least 50%

Ankle-Brachial Index (ABI) — required range option

ABI circulation criterion for DFUAnkle-Brachial Index (ABI) between 0.7 and 1.2 is acceptable evidence of adequate circulation

ABI clinical meaning

Prior Authorization, Documentation, and Step Therapy

Prior Authorization

Prior authorization required with documented failure of SOC

Prior authorization is required before skin substitute products will be considered medically necessary. The request must include documentation demonstrating failure of standard of care (SOC): for diabetic foot ulcers (DFU) a minimum of 4 weeks of SOC with documented compliance; for venous insufficiency ulcers minimum SOC durations as specified (≥4 weeks documented, and venous criteria note duration greater than 6 weeks). The PA must also show fulfillment of vascular, infection, glycemic and other criteria listed in the coverage section (eg, adequate circulation, no wound infection, appropriate glycemic control).

DFU: ≥4 weeks of documented SOC with compliance and failure to achieve ≥50% ulcer area reduction before skin substitute is initiated.
Venous ulcers: documented SOC (minimum 4 weeks; criteria specify duration greater than 6 weeks) with documented compliance prior to PA.
PA submission must include evidence that vascular, infection, and other eligibility criteria are met (eg, ABI/TcPO2/palpable pulses or duplex for venous disease).

Step Therapy

Key Terms and Abbreviations

CTPs — definition

DefinitionCellular and Tissue-Based Products (CTPs) are wound dressings or coverings that contain or consist of cells and/or tissue to promote wound healing

Clinical useCTPs are often used as alternatives to skin grafts for chronic wounds, burns, and ulcers

Product typesIncludes biologic, synthetic, or biosynthetic skin substitute products that replace dermal and/or epidermal layers

Chronic Wounds — definition / timeframe

DefinitionChronic wounds are wounds that have not progressed along the normal healing process, generally after a 4-week duration

ExamplesIncludes diabetic foot ulcers, chronic venous ulcers, and pressure ulcers that persist beyond expected healing timeframes

Clinical Background

Chronic wounds—such as diabetic foot ulcers, venous leg ulcers, and pressure injuries—fail to progress through normal healing phases and can cause substantial morbidity. Skin substitutes and cellular- and tissue‑based products (CTPs) may provide temporary coverage or regenerative support by replacing dermal and/or epidermal layers and are used when conventional therapies fail. Policy guidance limits use to situations where wounds are non‑infected, underlying contributors are managed, and conventional standard-of-care measures (for example, debridement, offloading for DFU, or sustained compression for venous ulcers) have been attempted and documented. The policy further restricts products that are liquid/gel formulations, experimental Q-code products, application to compromised wound beds (infected/ischemic/necrotic), frequent repeat applications without adequate response (≥50% volume or area reduction within assessment windows), and use when life expectancy precludes clinical benefit.

Policy Changes and Revision Timeline

2025-12-01effective_dateLatest

Policy effective date updated to 2025-12-01; multiple coverage and documentation sections consolidated under the Skin Substitutes policy.

2025-08-27revision

Approved at Committee and added life expectancy exclusion wording to II.B and expanded documentation requirements (D.II); added additional non-covered items and related policies.

2025-02-12

Policy Summary

PayerCareSource Georgia

PolicySkin Substitutes — Medical Policy (coverage criteria)

Policy CodePolicy N/A

Change TypeMaterial clinical updates (added circulation criteria, documentation expansion, life-expectancy exclusion)

Effective DateDec 1, 2025

Last ReviewAug 27, 2025

Next Review DateN/A

Key ActionObtain prior authorization with documentation of ≥4 weeks standard of care failure and required vascular and wound assessments before ordering skin substitutes.

SourceLink

On This Page

ABI compares blood pressure at the ankle with the arm; lower numbers indicate arterial narrowing or blockage

Alternative circulation measuresIf ABI unavailable, other accepted options include palpable pedal pulses, TcPO2 ≥30 mm Hg within 60 days, or triphasic/biphasic Doppler waveforms at the ankle

Transcutaneous oxygen (TcPO2) — threshold

TcPO2 thresholdTranscutaneous oxygen (TcPO2) ≥ 30 mm Hg measured within the last 60 days is required as one acceptable circulation demonstration

Use contextTcPO2 is an alternative to ABI or palpable pulses to demonstrate adequate limb perfusion for DFU coverage

Documentation windowTcPO2 measurement must be documented within the prior 60 days

Demonstrate prior/concurrent conventional therapies

Providers must document prior or concurrent use of conventional wound therapies before approval of skin substitutes. For DFU this includes offloading, appropriate dressings, and debridement as needed; for venous insufficiency ulcers this includes compression therapy, appropriate dressings (moist environment/NPWT), sharp debridement, and surgical intervention for UVD when applicable.

DFU: offloading (pressure relief), appropriate dressings, and debridement as needed.
Venous ulcers: compression therapy, surgical intervention for UVD if applicable, dressings to maintain a moist wound environment (eg, saline-moistened dressings, negative pressure wound therapy), and sharp debridement.

Documentation Required

Required comprehensive assessment and treatment‑plan documentation

Include a comprehensive assessment and treatment-plan documentation with the PA and chart: history, physical exam, vascular assessment/diagnostic tests, and disease‑specific evaluations. For DFU include diabetes assessment (A1c, management history, neuropathy/osteomyelitis comorbidities), offloading devices and footwear. For venous ulcers include prior ulcer history, BMI, thrombotic history, pregnancies/physical inactivity, venous reflux/perforator evaluation, and use of compression garments. The treatment plan must document debridement, evidence of offloading (DFU) or sustained compression (venous), infection control, exudate management, and smoking history/counseling.

Comprehensive patient assessment (history, exam, vascular assessment) and indicated diagnostic tests.
DFU: assessment of Type 1 or 2 diabetes including A1c, management history, comorbidities, and offloading/footwear.
Venous: clinical history items (prior ulcers, BMI, thrombotic history, pregnancies, physical inactivity), physical exam, evaluation of venous reflux/perforators/thrombosis, and documentation of compression garment use.
Treatment plan: debridement to a clean granular base, documented offloading for DFU, documented sustained compression for venous ulcers, infection control (removal of foreign body/focus of infection), exudate management, and documentation of smoking history, counseling, and cessation status.

Denial Risk

Denial triggers and application limits

Coverage may be denied for several conditions—providers must avoid these triggers. Denials include more than 3 applications within 12 weeks if wound volume has not decreased by at least 50%, repeat applications after an unsuccessful prior application, application on infected/ischemic/necrotic wound beds, use of liquid or gel skin substitute products, products not on the applicable fee schedule, and when the patient’s life expectancy would not allow clinical benefit.

>3 applications of a skin substitute over 12 weeks if wound volume has not decreased by ≥50%.
Repeat applications after an unsuccessful prior application (defined as increase in size/depth, no measurable change, or no sign of significant improvement).
Placement on infected, ischemic, or necrotic wound bed, or in patients with inadequate control of underlying/exacerbating conditions (eg, active infection, progressive necrosis, active Charcot arthropathy, active vasculitis, ischemia).
All liquid or gel skin substitute products or CTPs for ulcer care are non‑covered.
Skin substitute products not on the applicable fee schedule may be considered experimental and not reimbursable.
Application when life expectancy would not allow long‑term healing or clinical benefit.

Implication for coverageChronic designation (≥4 weeks) is required before considering skin substitutes under policy criteria

ABI — definition and clinical meaning

DefinitionAnkle-Brachial Index (ABI) is a comparison of blood pressure measured at the ankle with blood pressure measured at the arm to assess arterial perfusion

Clinical interpretationLower ABI values indicate arterial narrowing or blockage; ABI between 0.7 and 1.2 is consistent with adequate circulation for DFU coverage per policy

Role in policyABI is listed as one acceptable method to demonstrate adequate limb perfusion for diabetic foot ulcer coverage when within the specified range

Approved at Committee and updated references; added I.A.1-4 (circulation criteria for DFU) and other documentation/coverage clarifications.

2024-02-14revision

Updated references and made policy revisions per committee review.

2023-02-15creation

New Skin Substitutes policy issued (initial policy creation).